title: Galactocerebroside and not glucocerebroside or ceramide stimulate epidermal beta-glucocerebrosidase activity.
abstract: Glycosphingolipids including glucocerebroside (GluCer) and galactocerebroside (GalCer) have been recognized as bioreguratory lipids by our group and others. In addition, our recent study demonstrated that GalCer corrects dry skin conditions in humans. The processing of stratum corneum lipids, which occurs when beta-glucocerebrosidase (beta-GluCer'ase) changes GluCer to ceramide (Cer), is required to form the epidermal permeability barrier. We herein investigated the effects of GluCer, GalCer and Cer on the processing of GluCer to Cer by assaying epidermal beta-GluCer'ase in mice (155%, P < 0.01) when compared to vehicle treated controls, while neither GluCer nor Cer had this effect. Studies using inhibitors of beta-GluCer'ase or beta-galactosidase and measuring the optimum pH of the enzyme verified that GalCer specifically activated beta-GluCer'ase. We confirmed that GalCer significantly increased beta-GluCer'ase activity in the outer epidermal fraction (172%, P < 0.01) and that the activation of beta-GluCer'ase is not due to a direct activating effect of GalCer on the enzyme. Furthermore, the induction of beta-GluCer'ase activity by GalCer was also observed in cultured normal human deratinocytes (123%, P < 0.01). Finally, acylceramide content in stratum corneum was increased in mice treated with GalCer (194%, P < 0.0005). These results indicate that GalCer appears to affect the Cer construct in the stratum corneum by the activation of beta-GluCer'ase, which ultimately contribute to an enhancement of barrier formation.
authors.affiliation: Kanebo, Cosmetics Laboratory 3-28, Kanagawa-ken, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hara
authors.forename: Y
authors.initials: Y
authors.lastname: Uchida
authors.forename: A
authors.initials: A
authors.lastname: Haratake
authors.forename: K
authors.initials: K
authors.lastname: Mimura
authors.forename: S
authors.initials: S
authors.lastname: Hamanaka
mesh_terms: D000818:Animals; D002518:Ceramides / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D005699:Galactosylceramides / Q000032:analysis / Q000494:pharmacology*; D005962:Glucosylceramidase / Q000187:drug effects* / Q000378:metabolism*; D005963:Glucosylceramides / Q000494:pharmacology*; D006028:Glycosphingolipids / Q000378:metabolism; D006801:Humans; D008297:Male; D051379:Mice; D008812:Mice, Hairless; D012680:Sensitivity and Specificity; D012867:Skin / Q000737:chemistry / Q000201:enzymology; D013107:Sphingolipids / Q000494:pharmacology
chemical_list: D002518:Ceramides; D005699:Galactosylceramides; D005963:Glucosylceramides; D006028:Glycosphingolipids; D013107:Sphingolipids; D005962:Glucosylceramidase